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Heart transplantation (HT) programs are burdened with
a heavy responsibility. They are given a precious and limited
resource, donated organs, and are charged with distributing
them equitably to patients while at the same time maxi-
mizing clinical outcomes. Individual HT programs go to
great lengths to ensure that all patients enjoy the full promise
of HT, namely a return to a normal lifestyle without the risk
for premature death. For their part, the Organ Procurement
and Transplant Network contractor, the United Network for
Organ Sharing, has created an organ-allocation system
designed to be fair and balanced, and, even though it
requires tinkering from time to time, it is structured to
eliminate disparities in access.See page 2308Therefore, it is upsetting to know that, despite these noble
efforts, racial and ethnic disparities continue to exist within
the ﬁeld of HT. It has been recognized for years that black
and Hispanic patients with heart failure are less likely than
are white patients to be referred for transplantation, and that
outcomes in nonwhite transplant recipients are inferior to
those of white recipients (1–3). Black patients experience
higher rates of rejection, allograft failure, and death fol-
lowing transplantation compared with those in white,
Hispanic, and Asian recipients. They are less likely to
maintain a therapeutic level of immunosuppressant medi-
cation and are more likely to require hospitalization. Al-
though there is some good news in that the proportion of
transplantations performed in nonwhite patients has in-
creased over the past 2 decades, the gap in survival between
white and black recipients has not narrowed (2,4).*Editorials published in the Journal of the American College of Cardiology reﬂect the
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persistent disparities in HT outcomes (2–4). In general,
nonwhite patients listed for transplantation have been
younger, with a more adverse clinical risk proﬁle, including
higher rates of diabetes and renal failure. Black and Hispanic
patients tend to come from a more challenging socioeco-
nomic environment, with lower rates of college education
and higher rates of Medicaid/Medicare insurance, and from
neighborhoods with a lower mean income. Yet, even after
adjusting for these factors, the mortality rate in black
patients continues to exceed that in white and other
nonwhite recipients, suggesting that something other than
recipient, transplant, or socioeconomic factors explains these
differences.
It has been noted that the higher rates of death from graft
failure or other cardiovascular causes experienced in black
recipients may be a consequence of less intense immuno-
suppression (2). Compliance with immunosuppressive me-
dication has been reportedly lower in black HT recipients,
but the issue may be more complex than it seems. Self-
identiﬁed blacks and African Americans are more likely to
be expressers of the CYP3A5*1 genotype, which has been
associated with higher clearance and lower bioavailability of
tacrolimus (5). Such patients may require 2 to 4 times the
dose taken by so-called “slow metabolizers,” who are ho-
mozygous for the CYP3A5*3 allele and are more likely to be
white, Asian, or Hispanic. The perceived need for much
higher dosing to achieve a therapeutic drug level could be
mistakenly construed as noncompliance. The consequences
of underdosing on the physician’s part or missing a dose on
the patient’s part are likely to be greater in rapid, as opposed
to slow, metabolizers.
The role of human leukocyte antigen (HLA) matching in
determining transplantation outcomes has been controver-
sial. Due to genetic heterogeneity, nonwhite transplant
recipients typically have a greater degree of donor-to-
recipient HLA mismatch, and this may contribute to
higher rates of allograft rejection without necessarily re-
ducing survival (3). On the other hand, black patients have
higher levels of circulating HLA antibodies, which do
adversely affect clinical outcomes before and after trans-
plantation. Such sensitized patients with elevated panel
reactive antibody (PRA) concentrations wait longer to ﬁnd
a suitable donor, are less likely to receive a transplant, and
may have reduced survival after transplantation. Whether
there is a signiﬁcant effect of race and ethnicity on clinically
signiﬁcant sensitization, and whether such differences help
to explain the disparity in transplantation outcomes, remain
unclear.
In this issue of the Journal, Morris et al. (6) sought to
address this controversy by exploring the inﬂuence of race
and alloantibody sensitization on wait-list characteristics and
graft survival. They analyzed the Organ Procurement and
Transplant Network database for HTs performed between
2000 and 2012 and came to the following conclusions. First,
black and Hispanic patients have higher rates of graft failure
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highest in sensitized black patients. Second, HLA mismatch
does increase the likelihood of graft failure, and nonwhite
recipients are more likely than are white ones to have HLA
mismatch. Finally, despite having a higher PRA and greater
HLA mismatch, Asian transplant recipients appear less
likely to experience rejection or graft failure than white
recipients. Additionally, they conﬁrmed previous reports
showing that black, Hispanic, and sensitized patients wait
longer than others for a transplant. After transplantation,
among nonsensitized patients, blacks were the most likely to
be treated for rejection, whereas race/ethnicity had no
inﬂuence on the rate of treated rejection among those with
an elevated PRA.
Do immunologic differences fully explain the disparities
in graft survival between white and nonwhite transplant
recipients? In short, they do not. Although black patients
were more often sensitized, this difference was no longer
signiﬁcant after controlling for such things as age, renal
function, donor ischemic time, insurance status, level of
education, and HLA matching on multivariate analysis.
Black race itself remained a predictor of adverse graft
survival. On the ﬂipside of the coin, despite higher PRA and
greater HLA mismatch, Asian recipients enjoyed a graft
survival at least as high as that in whites. Therefore, although
sensitization, HLA mismatch, and lower socioeconomic
status were more prevalent among nonwhites, these factors
alone cannot explain the disparities encountered in black and
Hispanic recipients.
We are left with 2 profound questions:What then accounts
for the persistent discrepancies between various racial and
ethnic recipients?; and, most importantly: What do we do to
overcome them? This provocative report by Morris and
colleagues illuminates our understanding of the role of race
and encourages further research into healthcare disparities,
but cannot fully answer the ﬁrst question. Cultural insensi-
tivity, language barriers, bias, and other unaccounted for
socioeconomic factors may still be inﬂuencing transplantation
outcomes at a level that cannot be captured in currently con-
structed databases. Even in the present study, 40% of patients
were excluded from review due to incomplete data reporting,
and no adjustment was made for transplantation-center
volume. Black and Hispanic patients are more likely to
receive transplants at small-volume centers, which may affect
survival outcomes. Prospective observational trials, biomarkerresearch, and an improved understanding of pharmacoge-
nomics should help to elucidate the biological and behavioral
differences producing racial disparities.
In the meantime, even in the absence of a clear under-
standing of the complex origin of care disparities, one can
overcome them by being sensitive to the fact that race and
ethnicity inﬂuence outcomes. By instituting guideline-based,
protocolized care, by rigorously implementing performance-
improvement measures, and by ensuring access to care,
transplant programs should be able to provide quality care to
all recipients. Such programs that deliver intensive, com-
prehensive, multidisciplinary care have produced similar
survival rates in white and nonwhite patients, even in the
face of unequal rates of allograft rejection (3). This type of
care typically encompasses aggressive risk-factor modiﬁca-
tion, engages patients and families in disease-management
programs, and provides sufﬁcient levels of immunosup-
pression to prevent recurrent rejection and graft loss. This
multimodal approach should ensure that all patients enjoy
the full promise of HT, regardless of race or ethnicity.
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